Media coverage about GenVec (NASDAQ:GNVC) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. GenVec earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.5276813641197 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Shares of GenVec (NASDAQ:GNVC) traded up 0.000% during trading on Tuesday, reaching $7.193. GenVec has a 12-month low of $0.27 and a 12-month high of $10.44. The firm’s 50-day moving average is $6.74 and its 200 day moving average is $5.80.
TRADEMARK VIOLATION NOTICE: This piece was first posted by BBNS and is the sole property of of BBNS. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://baseballnewssource.com/markets/genvec-nasdaqgnvc-receiving-somewhat-favorable-media-coverage-report-shows-updated-updated/1249940.html.
GenVec Company Profile
GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.
Receive News & Ratings for GenVec Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenVec Inc and related companies with our FREE daily email newsletter.